ACS chemical neuroscience molecule spotlight on Valdoxen
1Vanderbilt University Medical Center, Department of Pharmacology and Vanderbilt Program in Drug Discovery, Vanderbilt University, Nashville, TN, USA, 37232-6600.
Abstract:
A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT(2C) receptor.
More Related Videos
10:29Multi-photon Intracellular Sodium Imaging Combined with UV-mediated Focal Uncaging of Glutamate in CA1 Pyramidal Neurons
Published on: October 8, 2014
08:31FM Dye Cycling at the Synapse: Comparing High Potassium Depolarization, Electrical and Channelrhodopsin Stimulation
Published on: May 24, 2018
Related Concept Videos
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Effects of Chemicals: Overview
Drugs Affecting Neurotransmitter Synthesis
Neurochemical Transmission: Sites of Drug Action
Drug Discovery: Overview
